Harmony Biosciences (HRMY) Financials

$34.50 -1.12 (-3.14%)

Closing price 04:00 PM Eastern

Extended Trading

$34.48 -0.02 (-0.06%)

As of 04:04 PM Eastern

Annual Income Statements for Harmony Biosciences

This table shows Harmony Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	146	129	181	35	-64	-187
Consolidated Net Income / (Loss)	145	129	181	35	-37	-152
Net Income / (Loss) Continuing Operations	145	129	181	35	-37	-152
Total Pre-Tax Income	192	173	105	37	-37	-152
Total Operating Income	191	192	120	88	17	-146
Total Gross Profit	558	461	354	250	132	4.42
Total Revenue	715	582	438	305	160	6.00
Operating Revenue	715	582	438	305	160	6.00
Total Cost of Revenue	157	121	83	56	28	1.58
Operating Cost of Revenue	157	121	83	56	28	1.58
Total Operating Expenses	367	269	234	162	115	150
Selling, General & Admin Expense	110	95	84	64	40	36
Marketing Expense	111	97	79	68	56	44
Research & Development Expense	146	76	71	30	19	70
Total Other Income / (Expense), net	0.98	-19	-16	-50	-54	-6.07
Interest Expense	17	34	19	50	23	0.00
Interest & Investment Income	19	15	3.13	0.22	-28	-6.07
Other Income / (Expense), net	-0.07	-	0.17	0.02	-3.07	0.00
Income Tax Expense	46	45	-77	2.83	0.00	0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.06	-0.15	0.15	0.00	-	-
Basic Earnings per Share	$2.56	$2.17	$3.07	$0.60	($2.48)	($24.07)
Weighted Average Basic Shares Outstanding	56.89M	59.47M	59.17M	57.53M	25.77M	7.78M
Diluted Earnings per Share	$2.51	$2.13	$2.97	$0.58	($2.48)	($24.07)
Weighted Average Diluted Shares Outstanding	57.87M	60.37M	61.10M	59.21M	25.77M	7.78M
Weighted Average Basic & Diluted Shares Outstanding	57.35M	56.77M	59.62M	58.87M	56.89M	-

This table shows Harmony Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	46	49	47	12	38	27	38	34	30	49	88
Consolidated Net Income / (Loss)	46	49	46	12	38	27	38	34	29	49	88
Net Income / (Loss) Continuing Operations	46	49	46	12	38	27	38	34	29	49	88
Total Pre-Tax Income	57	56	62	22	52	40	52	44	38	44	7.97
Total Operating Income	56	56	62	21	52	40	65	47	40	48	12
Total Gross Profit	153	147	143	141	127	125	128	109	98	101	94
Total Revenue	185	201	186	173	155	168	160	134	119	128	117
Operating Revenue	185	201	186	173	155	168	160	134	119	128	117
Total Cost of Revenue	32	54	43	32	27	43	32	25	21	27	23
Operating Cost of Revenue	32	54	43	32	27	43	32	25	21	27	23
Total Operating Expenses	96	91	82	119	75	85	63	62	58	54	82
Selling, General & Admin Expense	31	29	29	27	26	28	23	23	22	23	21
Marketing Expense	31	28	28	29	27	27	23	25	23	21	20
Research & Development Expense	35	35	25	64	22	30	17	15	13	10	41
Total Other Income / (Expense), net	0.93	0.43	0.46	0.34	-0.25	-0.67	-13	-2.81	-2.64	-3.51	-3.93
Interest Expense	3.84	4.21	4.35	4.40	4.54	4.80	17	6.22	5.73	-	0.00
Interest & Investment Income	5.04	4.48	4.93	4.71	4.43	4.10	4.11	3.44	3.09	15	-3.99
Other Income / (Expense), net	-0.28	0.16	-0.12	0.04	-0.14	-	-0.01	-0.03	0.00	0.07	0.06
Income Tax Expense	12	6.68	16	10	13	13	13	9.80	8.30	-4.41	-80
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.18	0.43	-0.73	0.06	0.17	-0.52	-0.01	0.49	-0.12	-0.03	0.15
Basic Earnings per Share	$0.79	$0.87	$0.81	$0.20	$0.68	$0.47	$0.64	$0.57	$0.49	$0.83	$1.48
Weighted Average Basic Shares Outstanding	57.31M	56.89M	56.87M	56.80M	56.77M	59.47M	59.86M	59.97M	59.73M	59.17M	59.23M
Diluted Earnings per Share	$0.78	$0.85	$0.79	$0.20	$0.67	$0.46	$0.63	$0.56	$0.48	$0.79	$1.44
Weighted Average Diluted Shares Outstanding	58.52M	57.87M	58.10M	57.54M	57.60M	60.37M	60.68M	60.74M	61.22M	61.10M	61.21M
Weighted Average Basic & Diluted Shares Outstanding	57.42M	57.35M	57.03M	56.83M	56.79M	56.77M	58.57M	60.00M	59.95M	59.62M	59.32M

This table details how cash moves in and out of Harmony Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Change in Cash & Equivalents	141	67	9.48	5.68	204	-59
Net Cash From Operating Activities	220	219	144	99	-2.99	-75
Net Cash From Continuing Operating Activities	220	219	144	99	-2.99	-75
Net Income / (Loss) Continuing Operations	145	129	181	35	-37	-152
Consolidated Net Income / (Loss)	145	129	181	35	-37	-152
Depreciation Expense	0.27	0.51	0.42	0.42	0.39	0.40
Amortization Expense	22	23	24	21	12	3.41
Non-Cash Adjustments To Reconcile Net Income	88	45	28	42	33	64
Changes in Operating Assets and Liabilities, net	-37	22	-90	0.63	-12	8.29
Net Cash From Investing Activities	-67	-46	-142	-100	-2.00	-127
Net Cash From Continuing Investing Activities	-67	-46	-142	-100	-2.00	-127
Purchase of Property, Plant & Equipment	-34	-37	-0.17	-0.30	-0.00	-0.15
Purchase of Investments	-105	-127	-111	0.00	0.00	-
Sale and/or Maturity of Investments	99	118	9.07	0.00	0.00	-
Other Investing Activities, net	-27	-	-40	-100	-2.00	-127
Net Cash From Financing Activities	-11	-106	6.84	7.42	209	144
Net Cash From Continuing Financing Activities	-11	-106	6.84	7.42	209	144
Repayment of Debt	-15	-210	-2.00	-232	-126	-5.18
Repurchase of Common Equity	0.00	-100	0.00	-0.30	-0.17	0.00
Issuance of Debt	0.00	200	0.00	200	200	100
Other Financing Activities, net	4.00	4.54	8.84	9.37	-12	0.09
Cash Interest Paid	17	20	16	20	26	4.23
Cash Income Taxes Paid	80	48	13	2.88	0.00	0.00

This table details how cash moves in and out of Harmony Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	36	66	70	-16	21	-13	7.19	29	44	-18	25
Net Cash From Operating Activities	34	76	71	43	31	77	63	37	43	27	55
Net Cash From Continuing Operating Activities	34	76	71	43	31	77	63	37	43	27	55
Net Income / (Loss) Continuing Operations	46	49	46	12	38	27	38	34	29	49	88
Consolidated Net Income / (Loss)	46	49	46	12	38	27	38	34	29	49	88
Depreciation Expense	0.01	0.01	0.01	0.09	0.16	0.16	0.14	0.10	0.10	0.11	0.10
Amortization Expense	5.68	5.64	5.59	5.51	5.55	5.46	6.49	5.71	5.74	5.95	6.38
Non-Cash Adjustments To Reconcile Net Income	13	11	12	54	11	12	18	8.22	6.93	8.16	7.24
Changes in Operating Assets and Liabilities, net	-30	9.10	6.87	-29	-24	33	-0.18	-11	0.30	-36	-46
Net Cash From Investing Activities	2.36	-7.19	0.75	-55	-6.19	-36	-0.81	-7.77	-1.79	-47	-32
Net Cash From Continuing Investing Activities	2.36	-7.19	0.75	-55	-6.19	-36	-0.81	-7.77	-1.79	-47	-32
Purchase of Property, Plant & Equipment	-0.13	-34	-0.00	-0.63	-0.01	-37	-	-0.21	0.00	-	-0.09
Purchase of Investments	-19	-36	-23	-21	-25	-22	-33	-25	-48	-55	-33
Sale and/or Maturity of Investments	22	30	24	26	19	23	32	18	46	8.20	0.87
Net Cash From Financing Activities	-0.35	-2.74	-1.18	-3.45	-3.63	-54	-55	-0.34	3.41	2.66	2.05
Net Cash From Continuing Financing Activities	-0.35	-2.74	-1.18	-3.45	-3.63	-54	-55	-0.34	3.41	2.66	2.05
Repayment of Debt	-3.75	-3.75	-3.75	-3.75	-3.75	-3.75	-205	-0.50	-0.50	-0.50	-0.50
Other Financing Activities, net	3.40	1.01	2.58	0.30	0.12	0.23	0.24	0.16	3.91	3.57	2.14
Cash Interest Paid	4.20	4.15	4.23	4.36	4.59	4.40	4.96	5.67	5.02	5.03	3.81

This table presents Harmony Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Total Assets	999	811	674	433	427	107
Total Current Assets	579	451	400	284	263	31
Cash & Equivalents	453	312	244	234	229	24
Short-Term Investments	14	42	79	0.00	-	-
Accounts Receivable	83	74	55	35	22	4.26
Inventories, net	7.20	5.36	4.30	4.43	3.82	1.09
Prepaid Expenses	14	13	9.35	7.64	6.96	1.44
Other Current Assets	8.12	5.54	8.79	3.22	1.30	0.26
Plant, Property, & Equipment, net	1.26	0.37	0.57	0.82	0.94	1.33
Total Noncurrent Assets	419	360	273	148	163	74
Long-Term Investments	109	72	23	0.00	-	-
Intangible Assets	113	137	161	144	162	72
Noncurrent Deferred & Refundable Income Taxes	190	144	86	0.00	-	-
Other Noncurrent Operating Assets	6.16	6.57	3.55	4.27	0.90	1.69
Total Liabilities & Shareholders' Equity	999	811	674	433	427	107
Total Liabilities	340	344	271	247	330	118
Total Current Liabilities	175	164	79	54	135	20
Short-Term Debt	16	15	2.00	2.00	0.00	-
Accounts Payable	14	18	3.79	1.00	2.56	6.36
Accrued Expenses	121	99	60	40	123	5.50
Current Employee Benefit Liabilities	19	24	12	9.17	8.94	7.92
Other Current Liabilities	5.67	7.81	1.62	1.36	0.31	0.12
Total Noncurrent Liabilities	165	181	192	193	195	98
Long-Term Debt	163	179	190	190	194	98
Other Noncurrent Operating Liabilities	1.95	2.11	2.50	3.18	1.11	0.16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	659	467	403	187	97	-423
Total Preferred & Common Equity	659	467	403	187	97	-423
Total Common Equity	659	467	403	187	97	-423
Common Stock	657	610	675	640	585	0.00
Retained Earnings	2.22	-143	-272	-454	-488	-423
Accumulated Other Comprehensive Income / (Loss)	0.07	0.00	-0.15	0.00	-	-

This table presents Harmony Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,056	928	858	847	778	760	715	643
Total Current Assets	643	522	458	480	463	456	418	382
Cash & Equivalents	489	387	317	333	325	317	288	261
Short-Term Investments	18	23	30	39	46	54	56	46
Accounts Receivable	106	82	83	80	67	64	53	55
Inventories, net	6.38	6.92	5.64	5.86	5.09	4.85	4.09	3.90
Prepaid Expenses	16	16	16	13	14	9.44	11	11
Other Current Assets	6.92	7.46	6.51	8.68	5.70	6.55	6.15	4.11
Plant, Property, & Equipment, net	1.38	0.75	0.75	0.21	0.43	0.57	0.47	0.68
Total Noncurrent Assets	411	405	399	367	314	304	248	261
Long-Term Investments	103	94	87	81	68	59	-	8.28
Intangible Assets	107	119	125	131	143	149	155	167
Noncurrent Deferred & Refundable Income Taxes	195	185	180	148	100	94	89	82
Other Noncurrent Operating Assets	6.21	6.52	6.74	7.24	3.09	2.71	3.62	3.83
Total Liabilities & Shareholders' Equity	1,056	928	858	847	778	760	715	643
Total Liabilities	335	331	320	332	296	275	272	300
Total Current Liabilities	175	161	147	154	112	93	85	107
Short-Term Debt	18	15	15	15	15	11	6.50	2.00
Accounts Payable	17	11	23	15	6.54	6.56	6.41	10
Accrued Expenses	113	110	92	92	73	64	57	86
Current Employee Benefit Liabilities	7.58	14	9.64	7.32	10	7.97	5.69	8.33
Other Current Liabilities	20	12	7.61	25	7.79	3.95	9.95	1.37
Total Noncurrent Liabilities	160	170	173	177	184	182	187	192
Long-Term Debt	158	168	171	175	182	180	185	190
Other Noncurrent Operating Liabilities	1.71	2.21	1.80	2.34	1.90	1.48	1.63	2.50
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	721	597	539	515	481	485	443	344
Total Preferred & Common Equity	721	597	539	515	481	485	443	344
Total Common Equity	721	597	539	515	481	485	443	344
Common Stock	673	644	632	621	652	694	686	665
Retained Earnings	48	-47	-93	-105	-170	-208	-243	-321
Accumulated Other Comprehensive Income / (Loss)	0.25	0.50	-0.23	-0.17	-0.52	-0.52	-0.03	-0.18

This table displays calculated financial ratios and metrics derived from Harmony Biosciences' official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	22.80%	32.93%	43.35%	91.21%	2,564.59%	0.00%
EBITDA Growth	-1.22%	48.96%	33.46%	308.91%	118.69%	0.00%
EBIT Growth	-0.66%	59.55%	37.48%	529.13%	109.54%	0.00%
NOPAT Growth	1.44%	-31.50%	157.50%	580.46%	111.64%	0.00%
Net Income Growth	12.91%	-28.99%	424.52%	193.65%	75.69%	0.00%
EPS Growth	17.84%	-28.28%	412.07%	123.39%	89.70%	0.00%
Operating Cash Flow Growth	0.20%	51.86%	46.58%	3,401.74%	96.04%	0.00%
Free Cash Flow Firm Growth	-25.07%	50.96%	21,912.47%	-104.32%	0.00%	0.00%
Invested Capital Growth	11.68%	-5.58%	72.56%	129.59%	1.45%	0.00%
Revenue Q/Q Growth	4.82%	7.40%	9.26%	12.91%	0.00%	0.00%
EBITDA Q/Q Growth	7.85%	-3.52%	15.91%	22.99%	0.00%	0.00%
EBIT Q/Q Growth	8.84%	-3.74%	18.77%	31.36%	0.00%	0.00%
NOPAT Q/Q Growth	18.07%	-15.61%	12.48%	30.26%	0.00%	0.00%
Net Income Q/Q Growth	18.65%	-14.53%	16.57%	196.28%	0.00%	0.00%
EPS Q/Q Growth	18.40%	-13.41%	16.02%	-89.45%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-0.50%	29.51%	-6.99%	38.67%	91.94%	0.00%
Free Cash Flow Firm Q/Q Growth	33.73%	5.38%	-13.60%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-4.58%	-2.15%	13.32%	-6.61%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	78.06%	79.17%	80.93%	81.82%	82.64%	73.69%
EBITDA Margin	29.84%	37.10%	33.11%	35.56%	16.63%	-2,370.34%
Operating Margin	26.70%	32.99%	27.45%	28.66%	10.63%	-2,433.76%
EBIT Margin	26.69%	32.99%	27.49%	28.66%	8.71%	-2,433.76%
Profit (Net Income) Margin	20.36%	22.14%	41.44%	11.33%	-23.13%	-2,535.06%
Tax Burden Percent	75.86%	74.31%	173.35%	92.44%	100.00%	100.00%
Interest Burden Percent	100.55%	90.30%	86.98%	42.75%	-265.50%	104.16%
Effective Tax Rate	24.15%	25.69%	-73.35%	7.56%	0.00%	0.00%
Return on Invested Capital (ROIC)	58.22%	59.00%	106.03%	78.18%	19.07%	-164.99%
ROIC Less NNEP Spread (ROIC-NNEP)	57.98%	66.17%	133.39%	198.93%	-230.66%	-232.81%
Return on Net Nonoperating Assets (RNNOA)	-32.38%	-29.37%	-44.45%	-53.79%	-105.39%	1,476.60%
Return on Equity (ROE)	25.84%	29.63%	61.58%	24.39%	-86.32%	1,311.62%
Cash Return on Invested Capital (CROIC)	47.18%	64.74%	52.78%	-0.46%	17.63%	0.00%
Operating Return on Assets (OROA)	21.07%	25.86%	21.74%	20.35%	5.21%	-136.74%
Return on Assets (ROA)	16.07%	17.35%	32.78%	8.04%	-13.84%	-142.43%
Return on Common Equity (ROCE)	25.84%	29.63%	61.58%	24.39%	328.47%	47,866.81%
Return on Equity Simple (ROE_SIMPLE)	22.07%	27.59%	45.05%	18.55%	-38.02%	35.94%
Net Operating Profit after Tax (NOPAT)	145	143	208	81	12	-102
NOPAT Margin	20.25%	24.52%	47.58%	26.49%	7.44%	-1,703.63%
Net Nonoperating Expense Percent (NNEP)	0.24%	-7.17%	-27.37%	-120.75%	249.73%	67.82%
Return On Investment Capital (ROIC_SIMPLE)	17.26%	21.60%	35.04%	-	-	-
Cost of Revenue to Revenue	21.94%	20.83%	19.07%	18.18%	17.36%	26.31%
SG&A Expenses to Revenue	15.44%	16.37%	19.19%	20.92%	24.88%	607.32%
R&D to Revenue	20.40%	13.07%	16.19%	9.94%	12.17%	1,160.88%
Operating Expenses to Revenue	51.36%	46.18%	53.49%	53.17%	72.00%	2,507.46%
Earnings before Interest and Taxes (EBIT)	191	192	120	88	14	-146
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	213	216	145	109	27	-142
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	2.98	4.05	8.11	13.37	21.16	0.00
Price to Tangible Book Value (P/TBV)	3.59	5.74	13.51	58.54	0.00	0.00
Price to Revenue (P/Rev)	2.75	3.25	7.46	8.16	12.87	21.41
Price to Earnings (P/E)	13.48	14.67	18.03	72.06	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	7.42%	6.82%	5.55%	1.39%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.97	7.07	12.52	17.00	32.20	9.90
Enterprise Value to Revenue (EV/Rev)	2.19	2.85	7.11	8.02	12.66	102.27
Enterprise Value to EBITDA (EV/EBITDA)	7.34	7.69	21.48	22.56	76.12	0.00
Enterprise Value to EBIT (EV/EBIT)	8.21	8.64	25.88	28.00	145.32	0.00
Enterprise Value to NOPAT (EV/NOPAT)	10.82	11.63	14.95	30.29	170.07	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.12	7.57	21.56	24.87	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	13.35	10.60	30.03	0.00	183.91	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.27	0.41	0.48	1.03	2.00	-8.45
Long-Term Debt to Equity	0.25	0.38	0.47	1.02	2.00	-8.45
Financial Leverage	-0.56	-0.44	-0.33	-0.27	0.46	-6.34
Leverage Ratio	1.61	1.71	1.88	3.03	6.24	-9.21
Compound Leverage Factor	1.62	1.54	1.63	1.30	-16.56	-9.59
Debt to Total Capital	21.38%	29.30%	32.24%	50.72%	66.65%	113.42%
Short-Term Debt to Total Capital	1.94%	2.27%	0.34%	0.53%	0.00%	0.00%
Long-Term Debt to Total Capital	19.44%	27.03%	31.90%	50.20%	66.65%	113.42%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	476.24%
Common Equity to Total Capital	78.62%	70.70%	67.76%	49.28%	33.35%	-489.66%
Debt to EBITDA	0.84	0.90	1.32	1.77	7.31	-0.69
Net Debt to EBITDA	-1.86	-1.07	-1.06	-0.39	-1.29	-0.52
Long-Term Debt to EBITDA	0.76	0.83	1.31	1.75	7.31	-0.69
Debt to NOPAT	1.24	1.36	0.92	2.37	16.34	-0.96
Net Debt to NOPAT	-2.74	-1.63	-0.74	-0.52	-2.89	-0.72
Long-Term Debt to NOPAT	1.13	1.25	0.91	2.35	16.34	-0.96
Altman Z-Score	5.30	4.97	8.48	6.60	2.98	-9.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	480.50%	-3,549.45%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	3.31	2.75	5.07	5.29	1.95	1.58
Quick Ratio	3.14	2.61	4.79	5.01	1.86	1.44
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	117	157	104	-0.48	11	0.00
Operating Cash Flow to CapEx	642.34%	588.50%	83,991.86%	33,072.82%	-149,250.00%	-50,628.19%
Free Cash Flow to Firm to Interest Expense	6.71	4.67	5.52	-0.01	0.49	0.00
Operating Cash Flow to Interest Expense	12.56	6.54	7.69	1.96	-0.13	0.00
Operating Cash Flow Less CapEx to Interest Expense	10.61	5.43	7.68	1.95	-0.13	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.79	0.78	0.79	0.71	0.60	0.06
Accounts Receivable Turnover	9.09	9.03	9.78	10.71	12.09	1.41
Inventory Turnover	24.97	25.10	19.13	13.45	11.30	1.45
Fixed Asset Turnover	878.05	1,233.10	628.65	347.49	140.87	4.51
Accounts Payable Turnover	9.96	11.27	34.88	31.22	6.22	0.25
Days Sales Outstanding (DSO)	40.13	40.41	37.34	34.07	30.20	259.06
Days Inventory Outstanding (DIO)	14.62	14.54	19.08	27.14	32.31	251.82
Days Payable Outstanding (DPO)	36.63	32.39	10.47	11.69	58.66	1,472.04
Cash Conversion Cycle (CCC)	18.12	22.56	45.96	49.51	3.85	-961.15
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	262	235	249	144	63	62
Invested Capital Turnover	2.87	2.41	2.23	2.95	2.56	0.10
Increase / (Decrease) in Invested Capital	27	-14	105	81	0.90	0.00
Enterprise Value (EV)	1,566	1,660	3,114	2,451	2,022	613
Market Capitalization	1,962	1,892	3,268	2,493	2,057	128
Book Value per Share	$11.56	$7.97	$6.79	$3.19	$1.71	($54.37)
Tangible Book Value per Share	$9.57	$5.63	$4.08	$0.73	($1.15)	($63.65)
Total Capital	838	661	594	378	291	86
Total Debt	179	194	192	192	194	98
Total Long-Term Debt	163	179	190	190	194	98
Net Debt	-397	-232	-154	-42	-34	73
Capital Expenditures (CapEx)	34	37	0.17	0.30	0.00	0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-47	-51	0.29	-1.65	-100	-13
Debt-free Net Working Capital (DFNWC)	420	302	323	233	128	12
Net Working Capital (NWC)	404	287	321	231	128	12
Net Nonoperating Expense (NNE)	-0.74	14	27	46	49	50
Net Nonoperating Obligations (NNO)	-397	-232	-154	-42	-34	73
Total Depreciation and Amortization (D&A)	23	24	25	21	13	3.80
Debt-free, Cash-free Net Working Capital to Revenue	-6.54%	-8.79%	0.07%	-0.54%	-62.78%	-214.38%
Debt-free Net Working Capital to Revenue	58.82%	51.94%	73.86%	76.17%	80.35%	193.58%
Net Working Capital to Revenue	56.55%	49.36%	73.40%	75.52%	80.35%	193.58%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.56	$2.17	$3.07	$0.60	($2.48)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	56.89M	59.47M	59.17M	57.53M	25.77M	0.00
Adjusted Diluted Earnings per Share	$2.51	$2.13	$2.97	$0.58	($2.48)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	57.87M	60.37M	61.10M	59.21M	25.77M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	57.35M	56.77M	59.62M	58.87M	56.89M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	145	143	84	81	12	-102
Normalized NOPAT Margin	20.25%	24.52%	19.21%	26.49%	7.44%	-1,703.63%
Pre Tax Income Margin	26.84%	29.79%	23.91%	12.25%	-23.13%	-2,535.06%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	10.90	5.73	6.40	1.74	0.61	0.00
NOPAT to Interest Expense	8.27	4.26	11.08	1.61	0.53	0.00
EBIT Less CapEx to Interest Expense	8.95	4.62	6.39	1.73	0.61	0.00
NOPAT Less CapEx to Interest Expense	6.32	3.14	11.08	1.60	0.53	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	77.61%	0.00%	0.87%	-0.45%	0.00%

This table displays calculated financial ratios and metrics derived from Harmony Biosciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.48%	19.51%	16.08%	28.76%	29.79%	31.26%	36.74%	25.40%	39.63%	40.67%	45.18%
EBITDA Growth	7.03%	34.29%	-5.57%	-48.76%	24.49%	-14.74%	285.83%	32.96%	39.51%	58.82%	-29.58%
EBIT Growth	7.86%	39.04%	-4.52%	-54.36%	28.37%	-15.71%	439.47%	41.36%	46.71%	66.37%	-43.21%
NOPAT Growth	16.36%	82.20%	-4.42%	-68.72%	22.09%	-48.54%	-63.56%	36.86%	24.61%	97.10%	791.41%
Net Income Growth	18.85%	85.95%	19.84%	-66.21%	30.01%	-45.15%	-56.27%	45.77%	37.24%	113.56%	1,014.17%
EPS Growth	16.42%	84.78%	25.40%	-64.29%	39.58%	-41.77%	-56.25%	43.59%	37.14%	107.89%	947.06%
Operating Cash Flow Growth	9.14%	-1.44%	11.73%	14.99%	-26.83%	187.37%	14.30%	9.88%	47.51%	-28.92%	81.45%
Free Cash Flow Firm Growth	-63.32%	-46.92%	-60.18%	-4.38%	200.59%	178.12%	-58.68%	-420.44%	-670.23%	4.68%	189.46%
Invested Capital Growth	13.59%	11.68%	14.52%	17.77%	3.97%	-5.58%	9.35%	37.68%	33.14%	72.56%	42.22%
Revenue Q/Q Growth	-8.22%	8.19%	7.65%	11.77%	-8.19%	5.08%	19.41%	12.67%	-7.16%	9.47%	9.51%
EBITDA Q/Q Growth	0.19%	-8.40%	148.86%	-53.14%	25.18%	-35.59%	35.03%	13.86%	-13.91%	191.49%	-53.47%
EBIT Q/Q Growth	0.15%	-9.25%	187.88%	-58.77%	28.48%	-37.68%	37.62%	15.95%	-15.23%	298.81%	-63.94%
NOPAT Q/Q Growth	-8.72%	7.31%	300.97%	-70.38%	42.94%	-43.71%	31.20%	15.65%	-39.76%	-60.14%	392.78%
Net Income Q/Q Growth	-7.91%	7.34%	297.66%	-69.76%	44.07%	-30.82%	12.13%	16.33%	-39.22%	-44.84%	273.73%
EPS Q/Q Growth	-8.24%	7.59%	295.00%	-70.15%	45.65%	-26.98%	12.50%	16.67%	-39.24%	-45.14%	269.23%
Operating Cash Flow Q/Q Growth	-55.02%	7.18%	65.43%	36.85%	-59.38%	21.50%	70.25%	-12.91%	59.53%	-51.67%	63.66%
Free Cash Flow Firm Q/Q Growth	-51.06%	98.99%	133.52%	-212.36%	-29.18%	49.28%	187.87%	-8.28%	45.00%	-178.95%	581.52%
Invested Capital Q/Q Growth	9.01%	-4.58%	-5.49%	15.54%	7.18%	-2.15%	-2.81%	2.00%	-2.66%	13.32%	22.37%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	82.68%	72.97%	77.01%	81.40%	82.22%	74.38%	79.85%	81.37%	82.56%	79.05%	80.41%
EBITDA Margin	33.37%	30.57%	36.11%	15.62%	37.26%	27.21%	44.39%	39.25%	38.84%	41.89%	15.73%
Operating Margin	30.45%	27.69%	33.17%	12.36%	33.65%	23.87%	40.25%	34.95%	33.93%	37.11%	10.15%
EBIT Margin	30.30%	27.77%	33.10%	12.38%	33.56%	23.87%	40.25%	34.92%	33.93%	37.17%	10.20%
Profit (Net Income) Margin	24.66%	24.58%	24.78%	6.71%	24.79%	15.80%	24.00%	25.56%	24.75%	37.81%	75.03%
Tax Burden Percent	79.68%	88.10%	74.14%	53.43%	74.03%	67.04%	74.20%	77.79%	78.04%	109.99%	1,103.84%
Interest Burden Percent	102.16%	100.48%	100.95%	101.41%	99.79%	98.74%	80.35%	94.08%	93.46%	92.49%	66.63%
Effective Tax Rate	20.32%	11.90%	25.86%	46.57%	25.97%	32.96%	25.80%	22.21%	21.96%	-9.99%	-1,003.84%
Return on Invested Capital (ROIC)	67.20%	70.12%	65.12%	16.11%	62.28%	38.50%	70.43%	63.60%	58.91%	90.95%	240.24%
ROIC Less NNEP Spread (ROIC-NNEP)	66.99%	70.00%	65.00%	16.03%	62.36%	38.68%	75.57%	65.03%	60.67%	94.88%	311.45%
Return on Net Nonoperating Assets (RNNOA)	-37.84%	-39.09%	-33.95%	-7.61%	-30.22%	-17.17%	-33.48%	-27.13%	-21.54%	-31.61%	-76.59%
Return on Equity (ROE)	29.36%	31.03%	31.17%	8.50%	32.06%	21.33%	36.95%	36.47%	37.37%	59.34%	163.64%
Cash Return on Invested Capital (CROIC)	43.45%	47.18%	34.07%	29.83%	56.69%	64.74%	64.65%	71.24%	71.41%	52.78%	64.20%
Operating Return on Assets (OROA)	23.72%	21.92%	26.46%	10.04%	26.54%	18.71%	30.69%	27.54%	27.15%	29.39%	7.90%
Return on Assets (ROA)	19.31%	19.41%	19.81%	5.44%	19.60%	12.38%	18.30%	20.15%	19.80%	29.90%	58.13%
Return on Common Equity (ROCE)	29.36%	31.03%	31.17%	8.50%	32.06%	21.33%	36.95%	36.47%	37.37%	59.34%	163.64%
Return on Equity Simple (ROE_SIMPLE)	21.20%	0.00%	20.55%	21.35%	26.72%	0.00%	31.32%	41.27%	42.77%	0.00%	45.27%
Net Operating Profit after Tax (NOPAT)	45	49	46	11	39	27	48	36	32	52	131
NOPAT Margin	24.26%	24.39%	24.59%	6.60%	24.91%	16.00%	29.87%	27.18%	26.48%	40.82%	112.08%
Net Nonoperating Expense Percent (NNEP)	0.21%	0.12%	0.12%	0.07%	-0.08%	-0.18%	-5.15%	-1.43%	-1.77%	-3.93%	-71.22%
Return On Investment Capital (ROIC_SIMPLE)	5.00%	5.86%	-	-	-	4.08%	-	-	-	8.81%	-
Cost of Revenue to Revenue	17.32%	27.03%	22.99%	18.60%	17.78%	25.62%	20.15%	18.63%	17.44%	20.95%	19.59%
SG&A Expenses to Revenue	16.91%	14.34%	15.37%	15.75%	16.61%	16.55%	14.07%	16.99%	18.52%	17.65%	18.20%
R&D to Revenue	18.70%	17.22%	13.65%	36.79%	14.35%	18.00%	10.92%	11.15%	11.16%	7.87%	34.60%
Operating Expenses to Revenue	52.23%	45.28%	43.84%	69.04%	48.57%	50.51%	39.60%	46.42%	48.62%	41.94%	70.26%
Earnings before Interest and Taxes (EBIT)	56	56	62	21	52	40	65	47	40	48	12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	62	62	67	27	58	46	71	53	46	54	18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.64	2.98	3.81	3.18	0.00	4.05	4.08	4.35	4.39	8.11	7.62
Price to Tangible Book Value (P/TBV)	3.10	3.59	4.76	4.14	0.00	5.74	5.81	6.28	6.76	13.51	14.81
Price to Revenue (P/Rev)	2.56	2.75	3.33	2.61	0.00	3.25	3.63	4.23	4.13	7.46	6.54
Price to Earnings (P/E)	12.43	13.48	18.39	14.86	0.00	14.67	13.07	10.56	10.28	18.03	16.09
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	8.05%	7.42%	5.44%	6.73%	0.00%	6.82%	7.65%	9.47%	9.73%	5.55%	6.22%
Enterprise Value to Invested Capital (EV/IC)	5.14	5.97	7.10	5.04	0.00	7.07	7.18	7.58	7.41	12.52	11.37
Enterprise Value to Revenue (EV/Rev)	1.97	2.19	2.86	2.23	0.00	2.85	3.18	3.75	3.80	7.11	6.23
Enterprise Value to EBITDA (EV/EBITDA)	6.76	7.34	9.87	7.27	0.00	7.69	7.71	10.94	11.35	21.48	19.96
Enterprise Value to EBIT (EV/EBIT)	7.54	8.21	11.14	8.23	0.00	8.64	8.65	12.74	13.47	25.88	24.63
Enterprise Value to NOPAT (EV/NOPAT)	9.72	10.82	15.92	11.81	0.00	11.63	10.20	8.53	8.48	14.95	13.48
Enterprise Value to Operating Cash Flow (EV/OCF)	6.60	7.12	8.83	6.86	0.00	7.57	10.18	11.59	11.34	21.56	16.07
Enterprise Value to Free Cash Flow (EV/FCFF)	12.57	13.35	22.24	18.27	0.00	10.60	11.61	12.32	11.85	30.03	20.79
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.24	0.27	0.31	0.35	0.37	0.41	0.41	0.39	0.43	0.48	0.56
Long-Term Debt to Equity	0.22	0.25	0.28	0.32	0.34	0.38	0.38	0.37	0.42	0.47	0.55
Financial Leverage	-0.56	-0.56	-0.52	-0.47	-0.48	-0.44	-0.44	-0.42	-0.36	-0.33	-0.25
Leverage Ratio	1.54	1.61	1.58	1.58	1.63	1.71	1.72	1.73	1.79	1.88	2.09
Compound Leverage Factor	1.57	1.62	1.60	1.60	1.63	1.69	1.38	1.63	1.68	1.74	1.39
Debt to Total Capital	19.60%	21.38%	23.45%	25.71%	26.93%	29.30%	29.06%	28.30%	30.19%	32.24%	35.80%
Short-Term Debt to Total Capital	1.95%	1.94%	1.92%	2.07%	2.13%	2.27%	2.21%	1.63%	1.02%	0.34%	0.37%
Long-Term Debt to Total Capital	17.65%	19.44%	21.53%	23.64%	24.81%	27.03%	26.84%	26.67%	29.16%	31.90%	35.42%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	80.40%	78.62%	76.55%	74.29%	73.07%	70.70%	70.94%	71.70%	69.81%	67.76%	64.20%
Debt to EBITDA	0.81	0.84	0.92	0.92	0.84	0.90	0.88	1.12	1.21	1.32	1.53
Net Debt to EBITDA	-2.00	-1.86	-1.63	-1.23	-1.16	-1.07	-1.08	-1.39	-0.96	-1.06	-0.99
Long-Term Debt to EBITDA	0.73	0.76	0.85	0.85	0.77	0.83	0.81	1.05	1.17	1.31	1.52
Debt to NOPAT	1.16	1.24	1.49	1.50	1.27	1.36	1.17	0.87	0.90	0.92	1.04
Net Debt to NOPAT	-2.88	-2.74	-2.63	-2.00	-1.76	-1.63	-1.43	-1.08	-0.72	-0.74	-0.67
Long-Term Debt to NOPAT	1.05	1.13	1.37	1.38	1.17	1.25	1.08	0.82	0.87	0.91	1.02
Altman Z-Score	4.88	4.85	5.47	4.34	0.00	4.35	5.19	5.65	5.22	8.13	5.75
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.67	3.31	3.24	3.13	3.11	2.75	4.12	4.90	4.90	5.07	3.56
Quick Ratio	3.50	3.14	3.05	2.93	2.93	2.61	3.90	4.67	4.64	4.79	3.38
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	11	22	11	-32	29	41	27	-31	-29	-52	66
Operating Cash Flow to CapEx	26,552.34%	225.01%	2,350,033.33%	6,743.20%	622,820.00%	206.79%	0.00%	18,079.51%	0.00%	0.00%	64,191.86%
Free Cash Flow to Firm to Interest Expense	2.76	5.15	2.50	-7.38	6.37	8.51	1.63	-5.00	-5.01	0.00	0.00
Operating Cash Flow to Interest Expense	8.86	17.95	16.21	9.68	6.87	15.99	3.76	5.96	7.43	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	8.83	9.97	16.21	9.53	6.87	8.26	3.76	5.93	7.43	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.78	0.79	0.80	0.81	0.79	0.78	0.76	0.79	0.80	0.79	0.77
Accounts Receivable Turnover	8.02	9.09	9.17	8.93	9.34	9.03	8.86	8.78	10.40	9.78	9.08
Inventory Turnover	26.36	24.97	24.26	25.74	25.72	25.10	23.36	21.11	20.62	19.13	17.10
Fixed Asset Turnover	936.33	878.05	1,157.69	989.61	1,808.23	1,233.10	978.19	787.46	774.50	628.65	495.68
Accounts Payable Turnover	9.90	9.96	17.05	9.24	11.87	11.27	12.66	14.46	13.45	34.88	10.46
Days Sales Outstanding (DSO)	45.50	40.13	39.82	40.88	39.10	40.41	41.20	41.57	35.10	37.34	40.20
Days Inventory Outstanding (DIO)	13.85	14.62	15.05	14.18	14.19	14.54	15.62	17.29	17.70	19.08	21.35
Days Payable Outstanding (DPO)	36.88	36.63	21.40	39.51	30.75	32.39	28.84	25.24	27.14	10.47	34.89
Cash Conversion Cycle (CCC)	22.46	18.12	33.46	15.55	22.54	22.56	27.98	33.63	25.66	45.96	26.65
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	286	262	275	291	252	235	240	247	242	249	220
Invested Capital Turnover	2.77	2.87	2.65	2.44	2.50	2.41	2.36	2.34	2.22	2.23	2.14
Increase / (Decrease) in Invested Capital	34	27	35	44	9.61	-14	21	68	60	105	65
Enterprise Value (EV)	1,469	1,566	1,952	1,466	0.00	1,660	1,725	1,872	1,794	3,114	2,496
Market Capitalization	1,903	1,962	2,273	1,713	0.00	1,892	1,966	2,110	1,947	3,268	2,620
Book Value per Share	$12.56	$11.56	$10.50	$9.48	$9.08	$7.97	$8.02	$8.09	$7.43	$6.79	$5.81
Tangible Book Value per Share	$10.69	$9.57	$8.40	$7.28	$6.77	$5.63	$5.64	$5.61	$4.83	$4.08	$2.99
Total Capital	896	838	780	725	705	661	678	677	635	594	536
Total Debt	176	179	183	186	190	194	197	191	192	192	192
Total Long-Term Debt	158	163	168	171	175	179	182	180	185	190	190
Net Debt	-435	-397	-322	-248	-264	-232	-241	-238	-152	-154	-124
Capital Expenditures (CapEx)	0.13	34	0.00	0.63	0.01	37	0.00	0.21	0.00	0.00	0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-47	-34	-20	-32	-51	-5.08	2.61	-4.65	0.29	-31
Debt-free Net Working Capital (DFNWC)	485	420	376	327	340	302	366	374	339	323	277
Net Working Capital (NWC)	468	404	361	312	325	287	351	363	333	321	275
Net Nonoperating Expense (NNE)	-0.74	-0.38	-0.34	-0.18	0.18	0.34	9.41	2.18	2.06	3.86	43
Net Nonoperating Obligations (NNO)	-435	-397	-322	-248	-264	-232	-241	-238	-201	-154	-124
Total Depreciation and Amortization (D&A)	5.68	5.65	5.59	5.60	5.71	5.63	6.64	5.81	5.84	6.06	6.48
Debt-free, Cash-free Net Working Capital to Revenue	-2.94%	-6.54%	-5.04%	-3.07%	-5.20%	-8.79%	-0.94%	0.52%	-0.99%	0.07%	-7.74%
Debt-free Net Working Capital to Revenue	65.12%	58.82%	55.16%	49.80%	55.10%	51.94%	67.46%	74.89%	71.92%	73.86%	69.05%
Net Working Capital to Revenue	62.77%	56.55%	52.96%	47.52%	52.67%	49.36%	64.69%	72.69%	70.54%	73.40%	68.55%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.79	$0.87	$0.81	$0.20	$0.68	$0.47	$0.64	$0.57	$0.49	$0.83	$1.48
Adjusted Weighted Average Basic Shares Outstanding	57.31M	56.89M	56.87M	56.80M	56.77M	59.47M	59.86M	59.97M	59.73M	59.17M	59.23M
Adjusted Diluted Earnings per Share	$0.78	$0.85	$0.79	$0.20	$0.67	$0.46	$0.63	$0.56	$0.48	$0.79	$1.44
Adjusted Weighted Average Diluted Shares Outstanding	58.52M	57.87M	58.10M	57.54M	57.60M	60.37M	60.68M	60.74M	61.22M	61.10M	61.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	57.42M	57.35M	57.03M	56.83M	56.79M	56.77M	58.57M	60.00M	59.95M	59.62M	59.32M
Normalized Net Operating Profit after Tax (NOPAT)	45	49	46	11	39	27	48	36	32	33	8.33
Normalized NOPAT Margin	24.26%	24.39%	24.59%	6.60%	24.91%	16.00%	29.87%	27.18%	26.48%	25.98%	7.11%
Pre Tax Income Margin	30.95%	27.90%	33.42%	12.55%	33.49%	23.57%	32.34%	32.85%	31.71%	34.37%	6.80%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	14.59	13.28	14.16	4.86	11.44	8.38	3.84	7.54	7.05	0.00	0.00
NOPAT to Interest Expense	11.68	11.67	10.52	2.59	8.49	5.62	2.85	5.87	5.50	0.00	0.00
EBIT Less CapEx to Interest Expense	14.56	5.30	14.16	4.71	11.44	0.65	3.84	7.51	7.05	0.00	0.00
NOPAT Less CapEx to Interest Expense	11.65	3.69	10.52	2.45	8.49	-2.11	2.85	5.83	5.50	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	40.77%	0.00%	0.00%	77.61%	33.17%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Harmony Biosciences' Financials

When does Harmony Biosciences's financial year end?

According to the most recent income statement we have on file, Harmony Biosciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Harmony Biosciences' net income changed over the last 5 years?

Harmony Biosciences' net income appears to be on an upward trend, with a most recent value of $145.49 million in 2024, falling from -$151.98 million in 2019. The previous period was $128.85 million in 2023. See where experts think Harmony Biosciences is headed by visiting Harmony Biosciences' forecast page.

What is Harmony Biosciences's operating income?

Harmony Biosciences's total operating income in 2024 was $190.83 million, based on the following breakdown:

Total Gross Profit: $557.92 million
Total Operating Expenses: $367.09 million

How has Harmony Biosciences revenue changed over the last 5 years?

Over the last 5 years, Harmony Biosciences' total revenue changed from $6.00 million in 2019 to $714.73 million in 2024, a change of 11,822.2%.

How much debt does Harmony Biosciences have?

Harmony Biosciences' total liabilities were at $340.05 million at the end of 2024, a 1.3% decrease from 2023, and a 187.5% increase since 2019.

How much cash does Harmony Biosciences have?

In the past 5 years, Harmony Biosciences' cash and equivalents has ranged from $24.46 million in 2019 to $453.00 million in 2024, and is currently $453.00 million as of their latest financial filing in 2024.

How has Harmony Biosciences' book value per share changed over the last 5 years?

Over the last 5 years, Harmony Biosciences' book value per share changed from -54.37 in 2019 to 11.56 in 2024, a change of -121.3%.

Related Companies

This page (NASDAQ:HRMY) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harmony Biosciences (HRMY) Financials

Frequently Asked Questions About Harmony Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harmony Biosciences (HRMY) Financials

Annual Income Statements for Harmony Biosciences

Quarterly Income Statements for Harmony Biosciences

Annual Cash Flow Statements for Harmony Biosciences

Quarterly Cash Flow Statements for Harmony Biosciences

Annual Balance Sheets for Harmony Biosciences

Quarterly Balance Sheets for Harmony Biosciences

Annual Metrics And Ratios for Harmony Biosciences

Quarterly Metrics And Ratios for Harmony Biosciences

Frequently Asked Questions About Harmony Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools